Intellia researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Their mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. As a leader in this space, they take this responsibility to patients seriously.
They are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, they are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Kaleidoscope Data Privacy Consultants (Kaleidoscope), through our office in London, is the UK representative for addressing matters related to the General Data Protection Regulation (GDPR).
If you have a question about how your personal data is processed, please select the form from the menu on the left. Here you will find details on how to contact Kaleidoscope, including a form to request a telephone call or to submit your question online.
More information about Intellia’s data protection policies may be found by clicking here. Intelliatx.com is Intellia’s company website, and will open in a new browser tab.
Contact details for our office in London:
Kaleidoscope Consultants Limited
East Side, Kings Cross, London N1C 4AX
www.kdpc.uk
+44 (0)20 3637 1111